J&J’s Comprehensive Approach To Finding A ‘Functional Cure’ For HBV

14 Nov 2016

Capsid assembly modulation, small-interfering RNA, a TLR7 agonist and a DNA-based vaccine are some of the components of the pharma’s strategy for bringing about significant advancement in hepatitis B therapy.

BOSTON – Janssen Pharmaceuticals Inc. is seeking to achieve a broad improvement in the treatment of hepatitis B, pursuing a “functional cure” via a variety of mechanisms and modalities that it hopes will come together in a combination therapy regimen similar to those that changed the landscape in HIV and hepatitis C.

The Johnson & Johnson subsidiary presented a set of posters and abstracts during the American Association for the Study...